Equities

Haemonetics Corp

Haemonetics Corp

Actions
  • Price (EUR)85.50
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change+4.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 30 2024202420232022
ASSETS
Cash And Short Term Investments179284259
Total Receivables, Net207179159
Total Inventory317259293
Prepaid expenses664744
Other current assets, total------
Total current assets769770756
Property, plant & equipment, net367364311
Goodwill, net565466467
Intangibles, net406276310
Long term investments------
Note receivable - long term------
Other long term assets815410
Total assets2,1961,9351,860
LIABILITIES
Accounts payable736458
Accrued expenses897266
Notes payable/short-term debt000
Current portion long-term debt/capital leases1012214
Other current liabilities, total128104104
Total current liabilities300252442
Total long term debt798754559
Total debt808766774
Deferred income tax633629
Minority interest------
Other liabilities, total757580
Total liabilities1,2361,1171,110
SHAREHOLDERS EQUITY
Common stock0.510.500.51
Additional paid-in capital635595572
Retained earnings (accumulated deficit)360253202
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(36)(30)(26)
Total equity960818749
Total liabilities & shareholders' equity2,1961,9351,860
Total common shares outstanding515051
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.